CA2323112A1 - Multigene vectors - Google Patents

Multigene vectors Download PDF

Info

Publication number
CA2323112A1
CA2323112A1 CA002323112A CA2323112A CA2323112A1 CA 2323112 A1 CA2323112 A1 CA 2323112A1 CA 002323112 A CA002323112 A CA 002323112A CA 2323112 A CA2323112 A CA 2323112A CA 2323112 A1 CA2323112 A1 CA 2323112A1
Authority
CA
Canada
Prior art keywords
construct
gene
expression
cell
cancer cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002323112A
Other languages
English (en)
French (fr)
Inventor
Brian D. Almond
Deborah Wilson
Sunil Chada
Louis A. Zumstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Introgen Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2323112A1 publication Critical patent/CA2323112A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002323112A 1998-03-16 1999-03-16 Multigene vectors Abandoned CA2323112A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7820598P 1998-03-16 1998-03-16
US60/078,205 1998-03-16
PCT/US1999/005781 WO1999047690A2 (en) 1998-03-16 1999-03-16 Multigene vectors

Publications (1)

Publication Number Publication Date
CA2323112A1 true CA2323112A1 (en) 1999-09-23

Family

ID=22142606

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323112A Abandoned CA2323112A1 (en) 1998-03-16 1999-03-16 Multigene vectors

Country Status (5)

Country Link
EP (1) EP1064392A2 (de)
JP (1) JP2002506651A (de)
AU (1) AU767880B2 (de)
CA (1) CA2323112A1 (de)
WO (1) WO1999047690A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3642601A (en) * 1999-11-05 2001-05-30 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
AU4764801A (en) * 2000-03-24 2001-10-08 Calydon Inc Cell-specific adenovirus vectors comprising an internal ribosome entry site
GB2362884A (en) * 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
AU2001291019A1 (en) 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
US7223740B2 (en) 2001-05-23 2007-05-29 Fornix Biosciences N.V. Vectors for enhanced expression of VEGF for atrial disease treatment
EP1262199A1 (de) * 2001-05-23 2002-12-04 Fornix Biosciences N.V. Vektoren zur gesteigerten Expression von VEGF zur Behandlung von Krankheiten
AU2002309335A1 (en) * 2001-05-23 2002-12-03 Fornix Biosciences N.V. Vectors for enhanced expression of vegf for disease treatment
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
EP1501861A4 (de) 2002-05-06 2007-06-20 Univ Texas Gezielt bindende proteine zur verabreichung therapeutischer oder diagnostischer reagentien
CN1944655B (zh) * 2006-09-04 2010-05-12 王尚武 靶向性共表达新型p53和p53AIP1的重组腺病毒
WO2014162318A2 (en) * 2013-03-30 2014-10-09 Usha Biotech Limited Methods and constructs for expressing biologically active proteins in mammalian cells
US20170044496A1 (en) 2014-04-10 2017-02-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
JP6837984B2 (ja) * 2015-10-23 2021-03-03 徹幸 平畑 遺伝子治療用組成物
CN108823208B (zh) * 2018-06-29 2021-11-02 中国科学院过程工程研究所 一种四环素诱导启动子及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
IL107250A (en) * 1993-10-12 2001-08-08 Yeda Res & Dev Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
DE19514310A1 (de) * 1995-04-18 1996-10-24 Univ Ludwigs Albert Vektoren zur Transfektion von eukaryotischen Zellen, deren Verwendung und damit transfizierte Zielzellen
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies

Also Published As

Publication number Publication date
JP2002506651A (ja) 2002-03-05
AU767880B2 (en) 2003-11-27
WO1999047690A2 (en) 1999-09-23
AU3094399A (en) 1999-10-11
EP1064392A2 (de) 2001-01-03
WO1999047690A3 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
US6630344B1 (en) Diminishing viral gene expression by promoter replacement
US6899870B1 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
ES2338288T3 (es) Metodo mejorado para la produccion y purificacion de vectores adenovirales.
AU767880B2 (en) Multigene vectors
CN1244215B (zh) 改进的腺病毒载体生产和纯化方法
US6855549B1 (en) Methods and compositions for increasing the infectivity of gene transfer vectors
US6420335B1 (en) Combination of radiotherapy and anti-angiogenic factors
PL186151B1 (pl) Zrekombinowane adenowirusy, kompozycje zawierające zrekombinowane adenowirusy, komórka gospodarza zainfekowana zrekombinowanym adenowirusem oraz sposób otrzymywania biologicznie aktywnego białka p53 typu dzikiego
US6251871B1 (en) P16 expression constructs and their application in cancer therapy
US20080044386A1 (en) Protamine-Adenoviral Vector Complexes and Methods of Use
AU762493B2 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
EP1029041A2 (de) Hyperthermischer induzierbarer expressionsvektor für gentherapie und verfahren zur ihre verwendung
US20080193484A1 (en) Novel Methods for Producing Adenoviral Vector Preparations with Reduced Replication-Competent Adenovirus Contamination and Novel Adenoviral Vectors and Preparations
US20060193832A1 (en) Use of the sodium iodine symporter to effect uptake of iodine
US6517828B1 (en) C-CAM as an angiogenesis inhibitor
US7052692B1 (en) Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
US7285542B2 (en) Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
JP2006519614A (ja) 悪性かつ形質転換した哺乳動物細胞を選択的に殺すペプチド
KR100217463B1 (ko) 암억제단백질인 p53을 생산하는 아데노바이러스 및 이를 항암치료에 사용하는 용도
WO1999011652A1 (en) Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead